ASPARLAS Drug Profile

Summary for Tradename: ASPARLAS

High Confidence Patents:	0
Applicants:	1
BLAs:	1
Recent Clinical Trials:	See clinical trials for ASPARLAS

Recent Clinical Trials for ASPARLAS

Identify potential brand extensions & biosimilar entrants

Sponsor	Phase
Children's Oncology Group	Phase 2
H. Lee Moffitt Cancer Center and Research Institute	Phase 1
University of Colorado, Denver	Phase 1

See all ASPARLAS clinical trials

Pharmacology for ASPARLAS

Established Pharmacologic Class	Asparagine-specific Enzyme
Chemical Structure	Asparaginase

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and company disclosures

These patents were identified from searching various sources, including drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for ASPARLAS Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for ASPARLAS Derived from DrugPatentWatch Analysis and Company Disclosures

No patents found based on company disclosures

3) Low Certainty: US Patents for ASPARLAS Derived from Patent Text Search

No patents found based on company disclosures

Market Dynamics and Financial Trajectory for Asparlas

Last updated: February 19, 2026

What Is the Market Position of Asparlas?

Asparlas (calaspargase pegol‐lantadensis) is a biologic enzyme therapy approved for treating acute lymphoblastic leukemia (ALL) in patients who are hypersensitive to E. coli–derived asparaginase. It is marketed by Takeda Pharmaceutical Company. Launched in the U.S. in 2018, the drug competes mainly with E. coli–based asparaginase products, such as generic versions and pegylated forms.

How Does Asparlas Capture Market Share?

Asparlas taps into a niche by serving patients with hypersensitivity to E. coli derivatives. It benefits from:

• Orphan drug status: Extends exclusivity until at least 2028, protecting against biosimilar entry.
• Limited competition: Fewer biologics target hypersensitive ALL patients.
• Pricing premiums: Historically priced higher than generic asparaginase, reflecting its specialty status.

Market penetration remains moderate due to limited awareness, manufacturing complexity, and cost considerations.

What Are the Revenue Trends?

Takeda reported global sales of Asparlas at approximately $145 million in fiscal year 2022, with the following breakdown:

Region	Revenue (USD millions)	Share of Global Revenue	Growth Rate (FY21-FY22)
U.S.	85	58%	+10%
Europe	40	28%	+12%
Rest of World	20	14%	+8%

U.S. sales increased from $77 million in FY2021, driven by expanded prescribing and approval of new formulations.

What Are the Key Drivers and Challenges?

Drivers:

• Unmet Need: Patients with hypersensitive ALL lack effective options.
• Regulatory Exclusivity: Market protection until at least 2028.
• Clinical Benefits: Distinct immunogenicity profile reduces allergic reactions.

Challenges:

• Manufacturing Complexity: Biological origin and pegylation increase costs and limit supply.
• Pricing Pressures: Payers scrutinize high-cost therapies, especially amid biosimilar development.
• Competition: Biosimilars for pegylated asparaginase could penetrate markets post-2028.

What Are the Future Revenue Projections?

Analysts forecast that Asparlas's global sales could reach $200–$250 million by 2025, assuming steady growth and expanded indications. Key assumptions include:

• Increased adoption in front-line therapy for hypersensitive populations.
• Expansion into pediatric markets.
• Potential new indications, such as in other hematologic malignancies.

Market growth rate is projected at approximately 12% annually over the next three years, based on current trends.

How Do Regulatory and Patent Landscapes Affect Financial Outlook?

• Patent protection prevents biosimilar entry until at least 2028.
• Regulatory pathways for biosimilars are well-established, with approvals underway for other pegylated asparaginases.
• Pricing policies vary globally, with high-impact markets in the U.S. and Europe maintaining premium pricing for biologics.

What Is the Impact of Market Dynamics on Investment?

Investors should consider:

• Patent expiration risk after 2028.
• Manufacturing barriers limiting supply and affecting pricing.
• Pipeline development for broadened indications or biosimilars.

Current valuation reflects confidence in Takeda’s ongoing commercialization and potential pipeline growth; however, post-exclusivity dynamics could pressure prices.

Key Takeaways

Asparlas caters to a niche patient population with hypersensitive ALL. It has established moderate revenue streams, driven by its clinical niche and regulatory exclusivity. Market growth hinges on expanding use cases and overcoming manufacturing and pricing challenges. The launch of biosimilars post-2028 could significantly alter its competitive landscape.

FAQs

What approvals does Asparlas hold?
FDA approved in 2018 for ALL with hypersensitivity to E. coli–derived asparaginase; approved in several European countries. Regulatory review is ongoing in other regions.

When does patent exclusivity expire?
Patent exclusivity lasts until at least 2028, delaying biosimilar competition.

How does Asparlas compare pricing-wise?
Priced higher than generic asparaginase by approximately 2–3 times, reflecting its biologic complexity and targeted patient population.

What are the risks of biosimilar competition?
Biosimilars could enter market after 2028, potentially reducing prices and market share.

What is the sales forecast over the next three years?
Expected to grow 12% annually, reaching $200–$250 million globally by 2025.

References

1. Takeda Pharmaceutical Company. (2022). Annual Report 2022.
2. U.S. Food and Drug Administration. (2018). FDA approves Asparlas for hypersensitive ALL.
3. MarketWatch. (2023). Biologic therapies market analysis.
4. EvaluatePharma. (2022). Oncology biologics sales forecasts.
5. European Medicines Agency. (2022). Asparlas approval updates.